Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.

The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4